RI
RTW Investments Portfolio holdings
AUM
$7.02B
This Quarter Return
+9.11%
1 Year Return
+28.16%
3 Year Return
+245.48%
5 Year Return
+425.65%
10 Year Return
+5,642.23%
AUM
$7.02B
AUM Growth
+$7.02B
(+7.4%)
Cap. Flow
+$119M
Cap. Flow
% of AUM
1.69%
Top 10 Holdings %
Top 10 Hldgs %
49.95%
Holding
78
New
10
Increased
26
Reduced
8
Closed
5
Top Buys
| 1 |
Neurocrine Biosciences
NBIX
|
$133M |
| 2 |
Zai Lab
ZLAB
|
$83.9M |
| 3 |
Quest Diagnostics
DGX
|
$72M |
| 4 |
Abbott
ABT
|
$60.4M |
| 5 |
Guardant Health
GH
|
$44.6M |
Top Sells
| 1 |
Axsome Therapeutics
AXSM
|
$147M |
| 2 |
Akero Therapeutics
AKRO
|
$104M |
| 3 |
Globus Medical
GMED
|
$82.4M |
| 4 |
RAPT Therapeutics
RAPT
|
$82.3M |
| 5 |
Alkermes
ALKS
|
$63M |
Sector Composition
| 1 | Healthcare | 99.89% |
| 2 | Financials | 0.11% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Madrigal Pharmaceuticals
MDGL
$9.76B
| $603M | 8.59% | 1,993,687 | – | – |
|
2
Natera
NTRA
$23.1B
| $438M | 6.24% | 2,593,645 +99 | +0% | +$16.7K |
|
3
PTC Therapeutics
PTCT
$3.92B
| $378M | 5.39% | 7,746,415 +263,288 | +4% | +$12.9M |
|
4
argenx
ARGX
$43.6B
| $371M | 5.29% | 673,497 | – | – |
|
5
Protagonist Therapeutics
PTGX
$3.67B
| $318M | 4.53% | 5,756,277 +36,862 | +0.6% | +$2.04M |
|
6
Insmed
INSM
$28.8B
| $310M | 4.42% | 3,084,558 +70,000 | +2% | +$7.04M |
|
|
7
Akero Therapeutics
AKRO
$3.74B
| $292M | 4.16% | 5,477,561 -1,941,779 | -26% | -$104M |
|
|
VRNA
8
Verona Pharma
VRNA
$9.16B
| $289M | 4.11% | 3,051,878 +203,078 | +7% | +$19.2M |
|
9
Avidity Biosciences
RNA
$5.99B
| $273M | 3.89% | 9,618,845 +871,919 | +10% | +$24.8M |
|
10
Stryker
SYK
$150B
| $234M | 3.33% | 590,517 +296 | +0.1% | +$117K |
|
11
Penumbra
PEN
$10.6B
| $222M | 3.16% | 863,553 +783 | +0.1% | +$201K |
|
12
Merus
MRUS
$4.98B
| $210M | 3% | 4,000,553 -168,840 | -4% | -$8.88M |
|
13
Acadia Pharmaceuticals
ACAD
$4.38B
| $194M | 2.76% | 8,995,547 +455,430 | +5% | +$9.82M |
|
|
14
Zai Lab
ZLAB
$3.68B
| $194M | 2.76% | 5,536,876 +2,400,196 | +77% | +$83.9M |
|
|
15
Axsome Therapeutics
AXSM
$6.05B
| $158M | 2.26% | 1,516,903 -1,405,826 | -48% | -$147M |
|
16
RadNet
RDNT
$5.52B
| $153M | 2.18% | 2,690,344 +372,762 | +16% | +$21.2M |
|
17
Immunocore
IMCR
$1.62B
| $153M | 2.18% | 4,869,798 | – | – |
|
|
18
Alkermes
ALKS
$4.78B
| $134M | 1.91% | 4,682,289 -2,202,409 | -32% | -$63M |
|
|
19
Neurocrine Biosciences
NBIX
$13.8B
| $133M | 1.9% | +1,062,072 | New | +$133M |
|
20
Tarsus Pharmaceuticals
TARS
$2.47B
| $126M | 1.8% | 3,111,680 -204,352 | -6% | -$8.28M |
|
21
Apogee Therapeutics
APGE
$2.17B
| $118M | 1.68% | 2,712,097 | – | – |
|
22
Masimo
MASI
$7.59B
| $115M | 1.64% | 683,294 | – | – |
|
23
Establishment Labs
ESTA
$1.2B
| $110M | 1.57% | 2,584,131 +244 | +0% | +$10.4K |
|
24
Intuitive Surgical
ISRG
$170B
| $110M | 1.57% | 202,456 | – | – |
|
25
Cytokinetics
CYTK
$4.23B
| $89.9M | 1.28% | 2,721,158 | – | – |
|